Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis

被引:23
作者
Petereit, HF
Bamborschke, S
Esse, AD
Heiss, WD
机构
[1] Klin./Poliklin. Neurol./P.N.M.E., Universität zu Köln
来源
MULTIPLE SCLEROSIS | 1997年 / 3卷 / 03期
关键词
multiple sclerosis; interferon beta therapy; interferon gamma; immunomodulatory therapy; indicator of therapeutical effectiveness;
D O I
10.1177/135245859700300302
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: We studied the individual course of interferon gamma producing blood lymphocyte count (IFGC) of 15 multiple sclerosis patients started on 8 MIU beta interferon administered subcutaneously each other day Methods: Mononuclear blood cells were prepared before treatment and on day 3, 9, 15, as well as after month 1, 2, 3 and 4 of therapy. After stimulation intracellular interferon gamma was detected with monoclonal fluorescent antibodies and measured by flowcytometry. IFGC is given as percentage of oil gated lymphocytes. Results: forty-eight hours after first interferon beta application the mean IFGC dropped significantly from 11.37 to 7.09 (P < 0.05) and to 4.22 within 4 months. Whereas the majority of patients showed a decrease of IFGC from the beginning of therapy in three of the 15 patients a transient increase of IFGC was seen suggesting a different response to immunomodulatory therapy. Conclusions: Interferon gamma producing lymphocyte count might be a useful tool to determine the biological effect of interferon beta therapy in multiple sclerosis patients.
引用
收藏
页码:180 / 183
页数:4
相关论文
共 34 条
[11]  
*IFNB MULT SCLER S, 1995, NEUROLOGY, V45, P1277
[12]   EFFECTS OF CORTICOSTEROIDS ON LYMPHOCYTE SUBPOPULATIONS AND LYMPHOKINE SECRETION IN CHICKENS [J].
ISOBE, T ;
LILLEHOJ, HS .
AVIAN DISEASES, 1992, 36 (03) :590-596
[13]   A BRIEF-HISTORY OF THE USE OF INTERFERONS AS TREATMENT OF MULTIPLE-SCLEROSIS [J].
JACOBS, L ;
JOHNSON, KP .
ARCHIVES OF NEUROLOGY, 1994, 51 (12) :1245-1252
[14]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[15]  
KATAYAMA K, 1993, GASTROENTEROL JPN, V28, P673
[16]   Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration [J].
Khan, OA ;
Xia, Q ;
Bever, CT ;
Johnson, KP ;
Panitch, HS ;
DhibJalbut, SS .
NEUROLOGY, 1996, 46 (06) :1639-1643
[17]   SYSTEMIC RECOMBINANT HUMAN INTERFERON-BETA TREATMENT OF RELAPSING-REMITTING MULTIPLE-SCLEROSIS - PILOT-STUDY ANALYSIS AND 6-YEAR FOLLOW-UP [J].
KNOBLER, RL ;
GREENSTEIN, JI ;
JOHNSON, KP ;
LUBLIN, FD ;
PANITCH, HS ;
CONWAY, K ;
GRANTGORSEN, SV ;
MULDOON, J ;
MARCUS, SG ;
WALLENBERG, JC ;
WILLIAMS, GJ ;
YOSHIZAWA, CN .
JOURNAL OF INTERFERON RESEARCH, 1993, 13 (05) :333-340
[18]  
LAROCCA AP, 1989, J INTERFERON RES S1, V9, P51
[19]  
LENGYEL P, 1981, INTERFERON, V3, P78
[20]   DOUBLE-BLIND RANDOMIZED PHASE-I STUDY ON THE CLINICAL TOLERANCE AND BIOLOGICAL EFFECTS OF NATURAL AND RECOMBINANT INTERFERON-BETA [J].
LIBERATI, AM ;
HORISBERGER, MA ;
PALMISANO, L ;
ASTOLFI, S ;
NASTARI, A ;
MECHATI, S ;
VILLA, A ;
MANCINI, S ;
ARZANO, S ;
GRIGNANI, F .
JOURNAL OF INTERFERON RESEARCH, 1992, 12 (05) :329-336